Search

An aetiopathogenetic analysis of non-endemic nasopharyngeal carcinoma (NPC) in European and Southern American patient groups was performed. Specifically, the study sought to determine the proportion of Epstein-Barr Virus (EBV)-positive tumour cells in NPC patients in two very different populations (Europe and South America) in areas not associated with a high incidence of NPC. Clinical data (age, sex and onset of clinical disease) were also analyzed. A total of 50 NPC samples, 24 from a European hospital (EH) and 26 from two South American hospitals (SAH), were included. Nuclear staining for Epstein-Barr virus-encoded small RNA (EBER) was performed by in situ hybridization (ISH). Latent membrane protein 1 (LMP1) expression was measured by immunohistochemical (IHC) analysis. A higher incidence of NPC was observed in patients40 years of age in EH; in SAH, by contrast, the incidence was higher in patients aged ≤ 40 years. Cervical lymph node metastasis was detected in 31 patients (of whom 84.6% were from SAH). A total of 72% of samples were EBERpositive; the incidence of EBER positivity was greater in type 3 NPCs. EBV was detected in a large proportion of epithelial cells in samples from both EH and SAH (75% vs. 69.2%, respectively). An association was found between EBER detection in lymphocytes and patient origin (p = 0.0001). LMP1 expression was detected in 64% of patients. ISH for the detection of EBER is the most sensitive technique for demonstrating EBV in tumour tissue. The incidence of EBV was not significantly greater in either of the study populations, but was significantly higher in patients with type 3 NPC. Definitive histological diagnosis of NPC was reached earlier in EH than in SAH, where metastases were more frequently diagnosed, suggesting that the disease had reached a more advanced stage by the time treatment was started.Scopo del nostro studio è stato confrontare i risultati dell'analisi eziopatogenetica sul carcinoma nasofaringeo non endemico (NPC) in pazienti europei e del Sud America ed in particolare determinare l'incidenza di cellule tumorali positive per Epstein-Barr Virus (EBV) nelle due diverse popolazioni. Sono stati inoltre analizzati i dati clinici (età, sesso e caratteristiche dell'insorgenza della malattia) al fine di evidenziare analogie e differenze nel confronto con i dati abitualmente rilevati nelle ampie casistiche disponibili. Sono stati analizzati un totale di 50 casi di NPC: 24 da ospedali europei e 26 da ospedali Sud Americani. La marcatura nucleare dell'RNA codificato dall'Epstain-Barr virus è stata ottenuta mediante ibridizzazione in situ. L'espressione della proteina latente di membrana (LMP1), è stata invece misurata mediante analisi immunoistochimica. Nei pazienti europei è stata osservata un'incidenza più alta di NPC nei casi di età superiore a 40 anni, nei pazienti del Sud America, invece, l'incidenza era maggiore nei casi di età inferiore/uguale a 40 anni di età. In 31 pazienti sono state riscontrate metastasi latero-cervicali linfonodali (di cui l'84.6% provenivano dal Sud America). Il 72% dei campioni è risultato positivo alla marcatura nucleare dell'RNA codificato dall'Epstain-Barr virus, con un'incidenza più alta nei casi di NPC di tipo 3. L'EBV è stato rilevato nella gran parte delle cellule epiteliali dei campioni provenienti sia dagli ospedali europei che sud americani (75% vs. 69.2%). Una correlazione statisticamente significativa è stata riscontrata fra la positività alla marcatura nucleare dell'RNA codificato dall'Epstain-Barr virus e le origini del paziente (p = 0.0001). L'espressione della LMP1 è stata rilevata nel 64% dei pazienti. In conclusione la detezione della marcatura nucleare dell'RNA codificato dall'Epstain Barr Virus mediante ibridizzazione è la metodica più sensibile per dimostrare la presenza di EBV nei campioni tumorali. In nessuna delle popolazioni studiate si è osservata una incidenza più alta, statisticamente significativa, di EBV, evidenziata, invece, nei pazienti con NPC di tipo 3. La diagnosi istologica definitiva è stata raggiunta prima negli ospedali Europei piuttosto che in quelli sud americani, nei quali alla diagnosi erano più frequentemente presenti metastasi laterocervicali, indicative di uno stadio tumorale più avanzato al momento dell'inizio del trattamento.

Submitted by Guilherme Lemeszenski (guilherme@nead.unesp.br) on 2014-02-26T17:17:15Z No. of bitstreams: 0 Made available in DSpace on 2014-02-26T17:17:15Z (GMT). No. of bitstreams: 0 Previous issue date: 2004-01-01 Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-20T13:37:03Z No. of bitstreams: 0 Made available in DSpace on 2014-05-20T13:37:03Z (GMT). No. of bitstreams: 0 Previous issue date: 2004-01-01 In developing countries, BL has a strong association with EBV infection during childhood. In South America, the data have shown an EBV association intermediate between that reported in the United States (30%) and that in equatorial Africa (95%). Early age at EBV infection and lower socioeconomic status have been related to increased EBV-associated BL in developing countries. In Brazil, there are not enough data on childhood BL related to EBV infection. Our aim was to evaluate the clinicopathologic features and EBV association of 44 children with NHL from the state of Rio de Janeiro, situated in the southeast of Brazil. EBV was detected using RNA in situ hybridization in 36 biopsy specimens. DNA from fresh tumor samples and from paraffin-embedded tissues of patients were analyzed by PCR, in which the first reaction included primers for an EBNA-2 common region while the nested reaction amplified the region discriminating between EBV types I and 2 in separate reactions. EBV was detected in 21 of 29 BLs (72%), and type I virus infected the majority of EBV-positive BLs (18/21). There was a trend for younger age in children with EBV-positive BL compared to EBV-negative BL (median age 4 compared to 6 years, respectively; p = 0.056). Our study confirmed that in the southeast of Brazil BL had an intermediate association with EBV. A higher rate of EBV-associated BL was described in the northeast of Brazil. These differences are probably related to regional socioeconomic status. In conclusion, our study suggests that early infection with EBV in the background of a low socioeconomic condition associated with other environmental factors could contribute to BL in Brazil. (C) 2003 Wiley-Liss, Inc. Hosp Canc, Serv Hematol, Inst Nacl Canc, Rio de Janeiro, Brazil Hosp Canc, Cell Markers Lab, Inst Nacl Canc, Rio de Janeiro, Brazil Hosp Canc, Dept Pathol, Inst Nacl Canc, Rio de Janeiro, Brazil Univ Estadual Paulista, Dept Pathol, Botucatu, SP, Brazil Univ Fed Rio de Janeiro, Dept Genet, Rio de Janeiro, Brazil Inst Nacl Canc, Bone Marrow Tranplantat Ctr, Rio de Janeiro, Brazil Hosp Canc, Inst Nacl Canc, Lab Cellular & Mol Hematol, Rio de Janeiro, Brazil Univ Estadual Paulista, Dept Pathol, Botucatu, SP, Brazil

Made available in DSpace on 2022-04-28T19:54:52Z (GMT). No. of bitstreams: 0 Previous issue date: 1999-07-01 We report the occurrence of aggressive vulval carcinoma associated with condyloma acuminata in three patients under 33 years old. Discussion of the role of the human papilloma virus (HPV) in the development of vulvar cancer is also presented. Three patients with condyloma associated with aggressive vulvar squamous cell carcinoma, in situ (1 case) and invasive (2 cases), documented by biopsy and/or vulvectomy are presented. In situ hybridization (ISH) was used to characterize the subtypes of HPV. One patient with erythematous systemic lupus developed in situ carcinoma after 5 years. The other two cases also developed aggressive multicentric, invasive squamous cell carcinoma after 10 years of diagnosis of condyloma. In all cases HPV cytological abnormalities were seen throughout the pathological examination. HPV 16 and 18 were present in cells of invasive squamous cell carcinoma in cases 2 and 3. HPV 6 and 11 were detected only in the condyloma area in case 2. HPV 30 was seen only in the condyloma area in case 3. This report emphasizes the need for biopsies of all unusually persistent or treatment-resistant condylomas, particularly in young and/or immunoisuppressed patients. Dept. of Gynecology and Obstetric State University of Saö Paulo, Botucatu Department of Pathology State University of Saö Paulo, Botucatu Depto. de Ginecologia e Obstetricia Faculdade de Medicina-UNESP, Botucatu, SP 18618-000 Depto. de Ginecologia e Obstetricia Faculdade de Medicina-UNESP, Botucatu, SP 18618-000

Submitted by Guilherme Lemeszenski (guilherme@nead.unesp.br) on 2014-02-26T17:07:07Z No. of bitstreams: 0 Made available in DSpace on 2014-02-26T17:07:07Z (GMT). No. of bitstreams: 0 Previous issue date: 1996-01-01 Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-20T15:29:26Z No. of bitstreams: 0 Made available in DSpace on 2014-05-20T15:29:26Z (GMT). No. of bitstreams: 0 Previous issue date: 1996-01-01 Both Epstein-Barr virus (EBV) types A and B are found in endemic Burkitt's lymphoma (BL) occurring in equatorial Africa. We studied 17 cases of Brazilian BL previously demonstrated to be EBV-positive to determine the EBV type as well as the presence of a characteristic 30 bp deletion within the 3' end of the latent membrane protein-1 (LMP-1) gene that may be important to the pathogenesis of several EBV-associated neoplasms. All case in which the age was known were children. We found type A EBV in 13 of 14 (93%) evaluable cases, and type B in one case. The LMP-1 deletion was found in 12 of 15 (80%) evaluable cases, including the one case of type B EBV, and a similar high prevalence (59%) of the deletion was detected in EBV-positive normal and reactive lymphoid tissues from individuals from the same geographic region. The high proportion of cases associated with type A EBV suggests that immunodeficiency is not an important factor in the pathogenesis of Brazilian BL, in contrast to endemic African BL. The presence of the LMP-1 deletion in a high prevalence in the normal population in this region is unexplained. CITY HOPE NATL MED CTR,DIV PATHOL,DEPT PATHOL,DUARTE,CA 91010 UNIV ESTADUAL PAULISTA JULIO MESQUITA FILHO,DEPT PATHOL,BOTUCATU,BRAZIL UNIV CAMPINAS,DEPT PATHOL,CAMPINAS,SP,BRAZIL UNIV ESTADUAL PAULISTA JULIO MESQUITA FILHO,DEPT PATHOL,BOTUCATU,BRAZIL

VCAM-1, a leukocyte adhesion molecule expressed by cytokine-activated endothelial cells in culture, may mediate mononuclear leukocyte infiltration in vessels and interstitium in solid organ allograft rejection. Using the avidin-biotin immunoperoxidase technique and two different antibodies--4B9, a murine monoclonal antibody, and rabbit polyclonal antisera to recombinant human VCAM (rVCAM Ab), which work in methacarn-fixed tissues--we studied the expression of this molecule in biopsies of transplanted liver and pancreas with and without features of rejection as well as nontransplant control tissues. The rVCAM Ab, but not 4B9, showed a population of reactive endothelial cells limited to sites of prominent subendothelial leukocytic cell infiltration in arteries and veins in rejecting allografts. VCAM-1 expression by sinusoidal endothelium in rejecting liver allografts was also observed. In addition, a population of cells (DC) with dendritic morphology was identified by rVCAM Ab within sites of lymphoid cell aggregations in both liver and pancreas allografts. Further evidence that these cells represent true DC was obtained by identification of VCAM-1 positive morphologically similar cells in both germinal centers and interfollicular areas of reactive lymph nodes; and by similar staining of these cells in allograft organs by a monoclonal antibody to nerve growth factor receptor, previously shown to recognize DC. DCs were generally not seen in normal control organs or portions of allografts uninvolved by lymphoid aggregates. This study provides evidence that 1) endothelial cell expression of VCAM-1 may be important in transplant rejection, 2) different epitopes of VCAM-1 may be preserved in tissue sections and recognized by different antibodies, and 3) there is probably a population of VCAM-1 expressing DC that participates in the cellular rejection progress.